For the first time in Nepal, genetic testing, also known as "Gene Sequencing," related to breast cancer (BRCA1 and BRCA2) has ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Professor Tutt's group is interested in therapy development for BRCA1/2 associated and Triple Negative forms of breast cancer, based on DNA Damage Repair (DDR) and in particular Homologous ...

Olaparib improved invasive disease-free survival, distant disease-free survival, and overall survival in high-risk ...

Patients with genetic alterations in the DNA repair genes BRCA1, BRCA2 or ATM who received olaparib had a median overall survival of 19.1 months, compared with 14.7 months for those on targeted ...